1. The document outlines different types of collaboration agreements that can be used in research and development, including research financing agreements, invention ownership agreements, and commercialization agreements. 2. Pros of collaboration include sharing risks and costs, accessing new technologies and markets, and increasing competitive advantage. Cons include lower level of control, potential communications issues, and higher costs if competition is reduced. 3. An example collaboration between GSK and HSCI is described, with the goals of hastening disease treatments through a $25 million stem cell science project over 5 years.

1. Presented By:-
Arvind Kumar (02)
Manoj Gupta (05)
Dharmender (07)
Rohit Kumar (31)
Gaurav Shah (39)
1

2. OUTLINE
model
Agreement structure
2

3. WHY COLLABORATION
3

4. COLLABORATIVE R &D
4

5. A. Research Alliance
Horizon will apply its genome editing technology GENESIS to develop human
isogenic disease model cell lines according to Boehringer’s specifications
5

6. B. Co - Development
The different parties agree to combine their
knowledge to create new innovative products
There are mainly two forms of co development deals
1. Either the two partners agree on a certain
division of ownership
2. They decide that one party gets the rights to
commercialise the drug in a certain geographical
area, and the other side gets the other
geographical rights
Eg. Eli-Lily with Genentech to develop recombinant
human insulin
6

7. C. Licensing
••In the R&D many products, especially
In the R&D many products, especially
pharmaceuticals, the costs can be get extremely high,
pharmaceuticals, the costs can be get extremely high,
causing companies to have second thoughts about the
causing companies to have second thoughts about the
possibility of drug development
possibility of drug development
••To achieve these goals, a growing number of
To achieve these goals, a growing number of
pharmaceutical companies are licensing proprietary
pharmaceutical companies are licensing proprietary
compounds or drug discovery related technologies from
compounds or drug discovery related technologies from
other companies to bolster their internal R&D efforts.
other companies to bolster their internal R&D efforts.
Lipitor --Pfizer’s blockbuster molecule that crossed $12
Lipitor Pfizer’s blockbuster molecule that crossed $12
billion sales in 2005 (used by over 45 million
billion sales in 2005 (used by over 45 million
People) was in-licensed by Yamanouchi
People) was in-licensed by Yamanouchi

9. Collaboration
• Merck-Advinus(2006)- Novel drug discovery & clinical
development collaboration in metabolic disorders,late stage
clinical studies.
• Eli- Li-ly-Shashun Chemicals(2002)-Agreement for mfg of
anti-TB drug to meet global demand,5 years contract, growth
changes from 10-43%.
• Dr Reddy’s –Merck Serono(2012)-To co-develop a portfolio
in oncology segment of Bio-similar molecule for multiple
markets .

10. Collaboration
• Nicholas Piramal-Pfizer(2006)-7-year agreement relating to
R&D services under which Nicholas Piramal will provide
process development and scale up services to Pfi zer’s animal
health division from the latter’s facilities in India
• Sanofi-aventis-Harvard University (2010)- biomedical
research in multiple therapeutic areas such as cancer, diabetes
and inflammation
Goal-adv. Knowledge in area of human health through basic
and applied research & to promote scientific exchange.

12. International collaboration is field-dependent
Numbers denote
number of articles
(thousands) in each
subject area in
2008
12

13. 13

14. AGREEMENTS IN RESEARCH AND DEVELOPMENT
• Research financing agreements
• Collaboration agreements
• Invention ownership agreements
• Confidentiality agreements
• Commercialization agreements
– Option
– License or technology transfer
– Trade
• Agreements to settle disputes
14

15. 15

16. PROS
16

17. CONS
– Collaborator's level of information security, risk
awareness and risk management is not adequate
– Communications issues/problems due to differences in
corporate and national cultures.
– Could lead to higher price of the technology by reducing
competition in the market
– There are risks involved in relying too heavily on one
collaborator, especially in strategic R&D.
– There is a possibility of communications issues/problems
due to differences in corporate and national cultures.
– Planning , checkpoints and evaluation at every step is
critical success parameter
17

18. • Domestic and international strategies and policies (science,
technology, innovation, entrepreneurship, nationwide,
regional, etc).
• International and domestic competition.
• Business decisions, investors.
• Political decisions.
• Human, financial and raw material resources; manpower and
salaries.
• Education, knowledge, know-how, skills.
• International agreements, legislation.
• Environment.
18

19. 19

20. • GSK and HSCI did a collaborative agreement for 5 years in
2008.
• It was a project of $25 Million plus in stem cell science to
hasten the development of treatments and cures for a range
of diseases.
Objective
20

21. • HSCI, a network of 700 scientists based at Harvard University
and its affiliated hospitals, claims to have the world largest
concentration of stem cell researchers. For GSK
• The GSK collaboration will help to keep it ahead of California’s
fast-growing stem cell centres, which are benefiting from a
huge infusion of state funds. For HSCI
21

22. • GSK will fund an annual grant in HSCI’s “seed grant” program,
which supports early stage innovative research. For HSCI
• The collaboration will integrate HSCI’s world-class stem cell
expertise with GSK’s pharmaceutical capabilities to drive
advances in
drug discovery research.
• This will include, for example, a staff exchange program
where HSCI and GSK researchers will spend up to several
months in each other’s laboratories.
22

23. Bristol-Myers Squibb and AstraZeneca
Collaboration

24. Deal Structure
• BMS and AstraZeneca has acquired Amylin.
• Development of anti-diabetic products-
Exenatide
• Profits and losses will be shared equally.
• AstraZeneca has rights over key strategic and
financial decisions.
• AstraZeneca will make a payment USD 3.4
billion in cash

25. Why Deal Extension ?
• Strengthens alliance leadership position in
diabetes
• Adds approved and marketed products for
Type 1 and 2 diabetes
• Combined development, regulatory and
commercial strengths of partners is expected
to unlock the potential of Amylin’s therapies
for the benefit of patients worldwide

26. 26